Here are relevant reports on : artificial-intelligence-ai-drug-discovery-market
-
Artificial Intelligence in Accounting Market by Component, Deployment Mode, Technology, Enterprise Size, Application (Automated Bookkeeping, Fraud and Risk Management, and Invoice Classification and Approvals), and Region - Global Forecast to 2024
The Artificial Intelligence in Accounting Market is expected to grow USD 4,791 million by 2024, at a Compound Annual Growth Rate (CAGR) of 48.4% during the forecast period. The major AI in accounting vendors include Microsoft (US), AWS (US), Xero (New Zealand), Intuit (US), Sage (England), OSP (US), UiPath (US), Kore.ai (US), AppZen (US), YayPay (US), IBM (US), Google (US), EY (UK), Deloitte (US), PwC (UK), KPMG (Netherlands), SMACC (Germany), OneUp (US), Vic.ai (US), Hyper Anna (Australia), Botkeeper (US), MindBridge Analytics (Canada), and Bill.com (US).
- Published: July 2019
- Price: $ 4950
- TOC Available:
-
Cell Based Assays Market by Offering (Consumables (Reagents, Assay Kits, Cell Lines, Microplates, Probes, Labels), Instruments & Software), Technology (Flow Cytometry, HTS), Application (Drug Discovery (Toxicity, PK/PD Studies)) - Global Forecast to 2030
The global cell-based assays market, valued at US$17.36B in 2024, is forecasted to grow at a 9.1% CAGR, reaching US$18.134B by 2025 and US$25.77B by 2030. Growth in this market is primarily driven by the increasing demand for drug discovery and development, the increasing preference for cell-based assays in drug discovery, and the rising prevalence of cancer.
- Published: April 2025
- Price: $ 4950
- TOC Available:
-
Glycomics Market / Glycobiology Market by Product (Enzymes (Glycosidases, Transferases), Instruments (Mass Spectrometry, Chromatography, Arrays), Kits, Carbohydrates, Reagents), Application (Drug Discovery, Diagnostics), End User - Global Forecast to 2027
The global glycomics market in terms of revenue was estimated to be worth $1.8 Billion in 2022 and is poised to reach $3.7 billion by 2027, growing at a CAGR of 15.5% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
- Published: November 2022
- Price: $ 4950
- TOC Available:
-
Protein Assays Market by Product (Reagent, Kit, Instruments), Type (Dye Binding, Test Strip), Application (Drug Discovery, Disease Diagnosis), Technology (Colorimetric, Fluorescence), End User (Pharmaceutical, Clinical Lab) - Global Forecasts to 2022
The protein assays market is projected to reach USD 2.41 Billion by 2022, at a CAGR of 11.1%. Some of the prominent players in the market are Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), General Electric Company (U.S.), and PerkinElmer Inc. (U.S.).
- Published: May 2017
- Price: $ 4950
- TOC Available:
-
Digital Twins in Healthcare Market by Component (Software, Services), Application (Personalized Medicine, Drug Discovery, Medical Education, Workflow Optimization), End User (Providers, Research & Academia, Payers), and Region - Global Forecast to 2030
The global digital twins in healthcare market, valued at US$2.69B in 2024, is forecasted to grow at a 68.0% CAGR, reaching US$4.47B by 2025 and US$59.94B by 2030. AI and machine learning algorithms can help analyze and interpret large volumes of data, identify trends, and forecast outcomes, particularly as data from sources like healthcare providers and payers become more accessible.
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
North America Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Service, Application (Drug Discovery, Diagnostic, Agriculture)-Forecast to 2030
The North America next-generation sequencing Market, valued at US$5.83 billion in 2024, stood at US$6.15 billion in 2025 and is projected to advance at a resilient CAGR of 13.6% from 2025 to 2030, culminating in a forecasted valuation of US$11.63 billion by the end of the period. The expansion of the North American NGS market is driven by increasing adoption of sequencing in oncology and precision medicine, the growing prevalence of cancer and other chronic diseases, and ongoing advances that lower sequencing costs while enhancing throughput and data quality.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
North America Proteomics Market by Instrumentation (Mass Spectrometry, HPLC, Electrophoresis, Protein Microarray), Reagent (Immunoassay), Service (Purification, Bioinformatics), Software, Application (Clinical, Drug Discovery)- Forecast to 2030
The North America Proteomics market, valued at US$13.06 billion in 2024, stood at US$14.11 billion in 2025 and is projected to advance at a resilient CAGR of 12.7% from 2025 to 2030, culminating in a forecasted valuation of US$25.62 billion by the end of the period. The growing use of proteomics in precision oncology, cardiology, and other complex diseases, together with strong momentum in clinical trials, is driving demand for high-throughput, reliable platforms in hospitals and research centers.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
NGS Sample Preparation Market by Product (Reagents & Consumables, Workstations), Workflow (Library Prep, Target Enrichment), Sample Type (DNA), Application (Diagnostics, Drug Discovery), Method (Microfluidic, Automated), End User & Region - Global Forecast to 2028
The global NGS sample preparation market in terms of revenue was estimated to be worth $1.9 billion in 2022 and is poised to reach $4.0 billion by 2028, growing at a CAGR of 13.4% from 2022 to 2028. The market for NGS sample preparation is highly consolidated, with key players strategizing to capture the market. Prominent players in the NGS sample preparation market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), PerkinElmer Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Danaher (US), Becton, Dickinson and Company (US), Merck KGAA (Germany), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Eurofins Scientific (Luxembourg), BGI (China), 10x Genomics (US), Sysmex Corporation (US), Psomagen (US), Zymo Research Corporation (US), Takara Bio Inc. (Japan), Novogene Co., Ltd. (China), New England Biolabs (US), Tecan Trading AG (US), Oxford Nanopore Technologies PLC (UK), PacBio (US), Medgenome (US), and Swift Biosciences Inc. (US).
- Published: March 2023
- Price: $ 4950
- TOC Available:
-
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
The global recombinant proteins market, valued at US$2.1 billion in 2022, stood at US$2.2 billion in 2023 and is projected to advance at a resilient CAGR of 7.2% from 2023 to 2028, culminating in a forecasted valuation of US$3.2 billion by the end of the period. Growth in the market can be attributed to factors such as rising incidence of chronic diseases, growing demand for biologics and biosimilars due to expiration of patents, rising demand for customized medicine and increasing government initiatives for R&D in life sciences research.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Asia Pacific Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Services, Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2030
The Asia Pacific Next-generation Sequencing market, valued at US$3.11 billion in 2024, stood at US$3.40 billion in 2025 and is projected to advance at a resilient CAGR of 16.7% from 2025 to 2030, culminating in a forecasted valuation of US$7.38 billion by the end of the period. Market growth is supported by substantial public and private investment in genomics, including national genome and precision medicine initiatives in China, Japan, India, South Korea, Singapore, and Australia, alongside ongoing advances that are lowering sequencing costs and improving throughput and data analytics.
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
